Table 5.
Frequency of responses across immunologic assays and antigens.
| Group | N | Serology | ASC | |||||
|---|---|---|---|---|---|---|---|---|
| IgG | IgA | IgA | ||||||
| CfaE | LTB | CfaE | LTB | CfaE | LTB | |||
| A | 1 µg dscCfaE | 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) |
| 2.6 µg Chimera | 5 | 5 (100) | 5 (100) | 1 (20.0) | 4 (80.0) | 1 (20.0) | 5 (100) | |
| 0.1 µg mLT | 5 | 0 (0.0) | 5 (100) | 0 (0.0) | 3 (60.0) | 0 (0.0) | 5 (100) | |
| B | 1 µg dscCfaE + 0.1 µg mLT | 5 | 4 (80.0) | 5 (100) | 3 (60.0) | 4 (80.0) | 3 (60.0) | 5 (100) |
| 2.6 µg Chimera + 0.1 µg mLT | 4 | 4 (100) | 4 (100) | 2 (50.0) | 4 (100) | 2 (50.0) | 4 (100) | |
| C | 5 µg dscCfaE + 0.1 µg mLT | 7 | 7 (100) | 7 (100) | 3 (42.9) | 5 (71.4) | 2 (28.6) | 6 (85.7) |
| 12.9 µg Chimera + 0.1 µg mLT | 7 | 7 (100) | 7 (100) | 3 (42.9) | 7 (100) | 4 (57.1) | 7 (100) | |
| D | 25 µg dscCfaE + 0.1 µg mLT | 10 | 9 (90.0) | 9 (90.0) | 5 (50.0) | 7 (70.0) | 6 (60.0) | 10 (100) |
Immunologic responses are limited to subjects receiving at least two vaccine doses. Serologic responses were identified as a ≥4-fold increase over baseline titer, and an ASC response was defined as a ≥2-fold increase over the baseline number of ASCs per 106 PBMCs or post-vaccination value > 1 ASC per 106 PBMCs if the baseline number of cells was 0 per 106 PBMCs. The adjuvant LT(R192G) is abbreviated as mLT.